Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estrone Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.79 |
| ▸ | STS | P08842 | 9/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.98 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.89 |
| ▸ | CA1 | P00915 | 3/20 | 0.79 |
| ▸ | CA2 | P00918 | 3/20 | 0.79 |
| ▸ | CA9 | Q16790 | 3/20 | 0.79 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.79 |
| ▸ | CA4 | P22748 | 1/20 | 0.79 |
| ▸ | CA6 | P23280 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone Sulfuric Acid SCHEMBL29369653 | 0.99 | STS (1.00) | STSABCC4ABCC1CYP2C9SLCO1B1 | |
| Estrone Sulfuric Acid SCHEMBL14375453 | 0.99 | STS (1.00) | STSABCC4ABCC1CYP2C9SLCO1B1 | |
| Estrone Sulfuric Acid SCHEMBL22846 | 0.99 | STS (1.00) | STSABCC4ABCC1CYP2C9SLCO1B1 | |
| Estrone Sulfuric Acid SCHEMBL6530673 | 0.99 | STS (1.00) | STSABCC4ABCC1CYP2C9SLCO1B1 | |
| Estrone Sulfuric Acid SCHEMBL12920398 | 0.99 | STS (1.00) | STSABCC4ABCC1CYP2C9SLCO1B1 | |
| Estrone Sulfuric Acid SCHEMBL22551312 | 0.98 | STS (0.98) | STSABCC4ABCC1CYP2C9SLCO1B1 | |
| Estrone Sulfuric Acid SCHEMBL29769589 | 0.98 | STS (0.98) | STSABCC4ABCC1CYP2C9SLCO1B1 | |
| Estrone Sulfuric Acid SCHEMBL21577 | 0.94 | CYP3A4 (1.00) | STSABCC4ABCC1CYP2C9SLCO1B1 | |
| Estrone Sulfuric Acid SCHEMBL4443808 | 0.94 | CYP3A4 (1.00) | STSABCC4ABCC1CYP2C9SLCO1B1 | |
| Estrone Sulfuric Acid SCHEMBL6556684 | 0.94 | CYP3A4 (1.00) | STSABCC4ABCC1CYP2C9SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-3716070-B1 | ADVANCED ERROR DETECTION FOR INTEGER SINGLE INSTRUCTION, MULTIPLE DATA (SIMD) ARITHMETIC OPERATIONS | INTEL CORP (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4581169-A2 | METHODS OF ENZYMATICALLY REPAIRING CLEAVED RNAS AND DETECTING THEREOF | The Johns Hopkins University (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-120051578-A | Method for enzymatic repair of cleaved RNA and detection method thereof | 约翰·霍普金斯大学 | 2025-05-27 | — | — | CN | disclosed |
| EP-4544305-A1 | METHOD FOR DIAGNOSING ENDOMETRIOSIS AND FOR CLASSIFYING THE STAGE OF ENDOMETRIOSIS | F. Hoffmann-La Roche AG (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-119404103-A | For diagnosing endometriosis and for treating uteruses method for classifying intimal dystopia by stage | 豪夫迈·罗氏有限公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2025026908-A1 | SERUM EPHA1 AS BIOMARKER FOR ENDOMETRIOSIS | ROCHE DIAGNOSTICS GMBH (DE) | 2025-02-06 | — | — | WO | disclosed |
| CN-119242718-A | Preparation and application of anti-tumor fermentation product of pseudomonas FD6 | 扬州大学 | 2025-01-03 | — | — | CN | disclosed |
| CN-119082210-A | Preparation and application of anti-tumor fermentation product of pseudomonas FD6 rpoS mutant | 扬州大学 | 2024-12-06 | — | — | CN | disclosed |
| EP-4433611-A2 | SYSTEMS AND METHODS FOR GENE EXPRESSION AND TISSUE OF ORIGIN INFERENCE FROM CELL-FREE DNA | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-115715330-A | System and method for inferring gene expression and tissue of origin from cell-free DNA | 小利兰·斯坦福大学托管委员会 | 2023-02-24 | — | — | CN | disclosed |
| WO-2022261235-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4065980-A1 | PROSTATE CANCER BIOMARKERS | Glycoscoredx Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| CN-112824529-B | Conditional gene knockout or rescue method | 北京大学 | 2022-09-09 | — | — | CN | disclosed |
| EP-4045685-A1 | METHODS AND SYSTEMS FOR MEASURING CELL STATES | Washington University (US) | 2022-08-24 | — | — | EP | disclosed |
| CN-114854782-A | Method for efficiently expressing recombinant polypeptide ligase with high activity | 华南理工大学 | 2022-08-05 | — | — | CN | disclosed |
| CN-114746559-A | Method and system for measuring cell status | 华盛顿大学 | 2022-07-12 | — | — | CN | disclosed |
| CN-112807304-B | Use of canagliflozin for the preparation of a medicament for the treatment of tuberous sclerosis-mediated diseases | 南京医科大学附属逸夫医院 | 2022-04-08 | — | — | CN | disclosed |
| WO-2022034317-A1 | BIOMARKERS IN PRIMARY BILIARY CHOLANGITIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2022-02-17 | — | — | WO | disclosed |
| EP-2648740-B1 | TRICALCIUM PHOSPHATE BINDING PEPTIDES AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007758-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) NON-PEPTIDE DRUG CONJUGATES AND USES THEREOF | SSTR4, SSTR1, SSTR3 | ESR1 1238/4885STS 1712/4885ABCC4 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.